Announcements Trials
Browse Landscape

Status

Completed 2Approved for marketing 2Withdrawn 1Unknown 1No longer available 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Pheochromocytoma 2Paraganglioma 2Recurrence 1Neuroblastoma 1Neoplasms 1

Interventions

3-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × Paraganglioma × 3-Iodobenzylguanidine × Clear all
NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡